The EVOKE trial (NCT04777396) is a pivotal Phase 3 clinical trial investigating oral semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in patients with early Alzheimer's disease. Sponsored by Novo Nordisk, this landmark trial represents the first large-scale Phase 3 evaluation of a GLP-1 receptor agonist for Alzheimer's disease treatment, extending beyond the drug's established use in type 2 diabetes and obesity.
Semaglutide works through multiple mechanisms that may be beneficial in Alzheimer's disease: reducing neuroinflammation, improving cerebral glucose metabolism, protecting mitochondrial function, and potentially reducing amyloid-beta toxicity. The trial specifically targets early-stage Alzheimer's disease patients, reflecting the growing recognition that disease-modifying interventions are most likely to succeed when initiated before significant neurodegeneration has occurred.
| Parameter |
Details |
| NCT Number |
NCT04777396 |
| Trial Name |
EVOKE |
| Phase |
Phase 3 |
| Status |
ACTIVE_NOT_RECRUITING |
| Sponsor |
Novo Nordisk A/S |
| Enrollment |
1,840 participants |
| Enrollment Type |
ESTIMATED |
| Study Type |
INTERVENTIONAL |
| Start Date |
May 18, 2021 |
| Completion Date |
January 23, 2026 |
| Last Updated |
January 29, 2026 |
Semaglutide is a long-acting GLP-1 receptor agonist that activates GLP-1 receptors throughout the body, including in key regions of the brain relevant to Alzheimer's disease pathology. GLP-1 receptor activation triggers intracellular signaling cascades that protect neurons and reduce pathological processes:
- cAMP/PKA Pathway: Increased cAMP activates protein kinase A, which phosphorylates multiple targets involved in neuronal survival
- PI3K/Akt Pathway: Activates the pro-survival Akt signaling pathway, inhibiting pro-apoptotic proteins
- ERK1/2 Pathway: Stimulates extracellular signal-regulated kinase signaling that promotes neuroplasticity
- AMPK Activation: Activates AMP-activated protein kinase, improving cellular energy metabolism
Semaglutide exerts neuroprotective effects through several interconnected mechanisms:
Neuroinflammation Reduction:
- Inhibits microglial activation and pro-inflammatory cytokine production
- Reduces neurotoxic astrogliosis
- Modulates peripheral immune cell infiltration into the brain
- Decreases NF-κB signaling in neural cells
Mitochondrial Protection:
- Enhances mitochondrial biogenesis through PGC-1α activation
- Reduces mitochondrial reactive oxygen species (ROS) production
- Improves mitochondrial respiration and ATP production
- Prevents mitochondrial membrane potential loss
Synaptic Protection:
- Preserves synaptic protein expression and function
- Protects dendritic spine morphology
- Enhances long-term potentiation (LTP)
- Reduces excitatory toxicity
Amyloid and Tau Modulation:
- Reduces amyloid-beta production via affects on APP processing
- May decrease tau phosphorylation
- Enhances cellular clearance mechanisms
- Protects neurons against amyloid toxicity
Semaglutide represents the most advanced GLP-1 receptor agonist in AD clinical development:
| Drug |
Developer |
Mechanism |
Stage |
Status |
| Semaglutide |
Novo Nordisk |
GLP-1 RA |
Phase 3 |
EVOKE trial |
| Liraglutide |
Novo Nordisk |
GLP-1 RA |
Phase 2 |
Completed |
| Exenatide |
AstraZeneca |
GLP-1 RA |
Phase 2 |
Parkinson's |
| Tirzepatide |
Eli Lilly |
GIP/GLP-1 |
Phase 2 |
Planning |
Growing evidence supports a metabolic component to Alzheimer's disease pathogenesis. The brain requires substantial glucose for energy, and cerebral glucose hypometabolism is an early feature of AD that precedes clinical symptoms by decades. This metabolic deficit compromises neuronal function and makes neurons vulnerable to pathological insults.
Evidence for Metabolic Dysfunction in AD:
- FDG-PET shows reduced cerebral glucose metabolism in AD-vulnerable regions
- Post-mortem studies reveal mitochondrial dysfunction
- Insulin signaling is impaired in AD brain
- Diabetes increases AD risk approximately 2-fold
GLP-1 receptors are expressed in brain regions affected by Alzheimer's disease:
- Hippocampus: Critical for memory formation
- Cerebral cortex: Involved in cognition
- Basal forebrain: Cholinergic neuron location
- Hypothalamus: Metabolic regulation
This widespread expression allows semaglutide to exert effects throughout the brain.
Extensive preclinical evidence supports GLP-1Ra development for AD:
Animal Model Studies:
- GLP-1Ra improve memory in APP/PS1 transgenic mice
- Reduce amyloid plaque burden and neuroinflammation
- Protect synaptic markers and neuronal numbers
- Improve cerebral glucose metabolism
- Reduce tau phosphorylation
Mechanistic Studies:
- Activate pro-survival signaling in neurons
- Reduce oxidative stress markers
- Improve mitochondrial function
- Modulate microglial activation
Semaglutide has demonstrated:
- Significant weight loss in T2D patients
- Cardiovascular risk reduction
- Improved kidney outcomes
- Good safety profile over multi-year use
These established effects suggest potential benefits for AD patients, who often have comorbid metabolic conditions.
¶ Phase 3 Randomized Structure
The EVOKE trial employs a rigorous randomized, double-blind, placebo-controlled design:
- Enrollment: 1,840 participants with early AD
- Randomization: 1:1 ratio to semaglutide or placebo
- Duration: Up to 104 weeks (2 years)
- Dosing: Oral semaglutide, starting at low dose with titration
- Semaglutide Arm: Oral semaglutide at target dose
- Placebo Arm: Matching oral placebo
- Early AD Population: Confirmed early-stage Alzheimer's disease
- Biomarker Confirmation: Amyloid positivity via PET or CSF
- Fixed Dose Escalation: Standard titration to target dose
- Comprehensive Monitoring: Regular cognitive and functional assessments
- Biomarker Substudies: Imaging and fluid biomarker collections
The trial enrolls patients with early Alzheimer's disease who meet specific criteria:
- Diagnosis: MCI due to AD or mild AD dementia per NIA-AA criteria
- Age: Typically 55-85 years
- Cognitive Status: MMSE 20-30
- Amyloid Status: Confirmed amyloid positivity
- Age 55-85 years
- Meet NIA-AA criteria for MCI due to AD or mild AD dementia
- Confirmed amyloid pathology (PET or CSF biomarker)
- MMSE score 20-30
- CDR global score of 0.5 or 1.0
- Stable on background AD medications (if applicable)
- Able to comply with study procedures
- History of stroke or significant cerebrovascular disease
- Active neurological conditions other than AD
- Psychiatric conditions that could interfere with assessment
- Uncontrolled diabetes mellitus
- Contraindications to MRI or PET
- Previous GLP-1 RA treatment
- Significant medical conditions
¶ Primary and Secondary Endpoints
Change in Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score
The CDR-SB is a validated global measure of dementia severity:
- Assesses six domains: Memory, Orientation, Judgment, Community Affairs, Home/Hobbies, Personal Care
- Each scored 0-3, summed to 0-18 (higher = worse)
- Clinically meaningful change: 0.5-1.0 points
-
Cognitive Measures
- ADAS-Cog14: Alzheimer's Disease Assessment Scale-Cognitive
- MMSE: Mini-Mental State Examination
- RBANS: Repeatable Battery for Neuropsychological Status
-
Functional Measures
- ADCS-ADL: Alzheimer's Disease Cooperative Study-Activities of Daily Living
- FAQ: Functional Activities Questionnaire
-
Biomarker Measures
- Amyloid PET: Regional and global SUVr change
- Tau PET: Regional tau accumulation
- CSF biomarkers: Aβ42/40, p-tau, total tau
- Blood biomarkers: Neurofilament light chain (NfL)
-
Safety and Tolerability
- Adverse event incidence
- Laboratory parameters
- Vital signs and weight
The EVOKE trial represents a significant advancement in several ways:
- Novel Mechanism: First large-scale Phase 3 trial of GLP-1Ra in AD
- Disease Modification Focus: Targets underlying pathology, not just symptoms
- Metabolic Link: Addresses the brain's energy dysfunction in AD
- Repurposing Potential: Established safety profile accelerates development
If successful, semaglutide could:
- Provide New Treatment Option: First metabolic therapy for AD
- Address Comorbidities: Benefit patients with metabolic syndrome
- Enable Combination: Work with amyloid-targeted agents
- Improve Outcomes: Slow cognitive and functional decline
¶ Competitive Landscape
Several metabolic approaches have been investigated in AD:
| Approach |
Developer |
Mechanism |
Status |
| Semaglutide |
Novo Nordisk |
GLP-1 RA |
Phase 3 |
| Benfotiamine |
ATRI |
Thiamine activation |
Phase 2 |
| Pioglitazone |
Takeda |
PPARγ agonist |
Phase 3 (discontinued) |
| Metformin |
Various |
AMPK activation |
Phase 3 |
The EVOKE trial is distinguished by its rigorous Phase 3 design and comprehensive biomarker program.
Semaglutide has an established safety profile from extensive use in diabetes:
- Gastrointestinal: Nausea, vomiting, diarrhea (common, usually transient)
- Pancreatitis: Rare but reported
- Gallbladder Disease: Increased risk of gallstones
- Thyroid C: Rare in humans (警示ed in rodents)
The trial includes comprehensive safety monitoring:
- Regular physical examinations
- Laboratory assessments including lipase/amylase
- Adverse event documentation
- Imaging for pancreatitis symptoms
Amyloid PET:
- Confirms baseline amyloid positivity
- Quantifies amyloid plaque change with treatment
- Correlates amyloid reduction with clinical outcomes
Tau PET:
- Assesses baseline tau burden
- Measures treatment effects on tau accumulation
- Explores amyloid-tau relationship
Core CSF biomarkers:
- Aβ42/40 ratio: Amyloid pathology
- Phosphorylated tau: Tau pathology
- Total tau: Neurodegeneration
- Neurofilament light: Axonal injury
Blood-based markers for monitoring:
- NfL: Neurodegeneration marker
- GFAP: Astrocyte activation
- p-tau181: Tau pathology
The metabolic approach of semaglutide differs fundamentally from amyloid-targeted antibodies:
| Aspect |
Amyloid-Targeted |
Metabolic Therapy |
| Target |
Amyloid plaques |
Cellular metabolism |
| Mechanism |
Immunotherapy |
Receptor agonism |
| Approach |
Remove pathology |
Support function |
| Stage |
Early intervention |
Broader applicability |
| Combination |
Limited |
Excellent |
This complementary mechanism could enable future combination therapies.
¶ Proteins and Genes